Author

Haoyi Hou

Boston UniversityPrimary ORCID profile (0009-0001-3985-7541 · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Haoyi HouiD1 paper · Sartorius Stedim North America Inc.;

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:deep learning· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

Arturo J. VegasiD· 2 shared RaaviiD· 2 shared Sean P. QuinnelliD· 2 shared Andrea CasiraghiiD· 1 shared Angela N. KoehleriD· 1 shared Becky S. LeiferiD· 1 shared Benjamin LeuiD· 1 shared Chandler Ruping· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Arturo J. VegasORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Surveying the target tractability of cytokines with small molecules

Raavi, Sean P. Quinnell, Andrea Casiraghi, Becky S. Leifer, Benjamin Leu, Morgan Stilgenbauer, Fiona Wang, Haoyi Hou, Angela N. Koehler, Arturo J. Vegas

This study identifies small-molecule ligands and inhibitors for 32 cytokines, showing their tractability for small-molecule modulation and providing insights into chemical structures that enable cytokine inhibition.

bioRxiv · Apr 23, 2026 · PreprintImmunology

Potent and Selective IL-4 Inhibitors with Anti-Tumor Activity

Raavi, Imron Chaudhry, Daniel F. Sheehy, Sean P. Quinnell, Chandler Ruping, Jacob W. Lee, Sha Hu, Haoyi Hou, Pinghua Liu, Arturo J. Vegas

This paper identifies potent and selective IL-4 inhibitors that show anti-tumor activity in murine models.

bioRxiv · Feb 4, 2026 · PreprintCancer Biology